PHMB PharmaCom BioVet Inc (CE)

PharmaCom BioVet, Inc. (PINKSHEETS: PHMB) is pleased to announce a formal collaborative agreement with PetScreen, LTD, BioCity Nottingham, UK, to help improve cancer diagnosis and treatment for canines. PetScreen is the leading innovator of early detection of canine cancer. With one in three dogs developing cancer, early detection increases the chance of successful treatment and survival.

Dr. Kevin Slater, Chief Executive Officer of the PetScreen, LTD Board of Directors, confirmed his company's participation by stating, "I am very pleased that our two companies have agreed to collaborate both commercially and technically to implement a range of new technologies aimed at improving cancer diagnosis and treatment in companion animals. We believe that this collaboration will go a long way toward achieving our mutual goals," concluded Slater.

PetScreen, LTD, formally incorporated in 2004 by Slater and board Chairman, Professor Graeme Radcliffe, was founded by people who have lost their pets to cancer and by experienced scientists who have worked on new methods for the detection and treatment of cancer in companion animals. They use the latest proven scientific developments to provide veterinarians with improved testing methodologies to help them make better diagnostic and treatment decisions for companion animals with cancer.

PetScreen, LTD is actively engaged in a comprehensive profile of services, combining testing, treatment and networking of national and international collaborators to provide services and support to the veterinary cancer patient. Gary Berthold, President and CEO of PharmaCom BioVet, Inc., added his enthusiasm for the agreement saying, "In forming this cooperative relationship with PetScreen, LTD, we are continuing to broaden our links with cancer scientists and veterinary leaders on a world-wide basis; thus increasing the opportunities for a greater range of research, diagnosis and treatment technologies, and hastening the progress towards treatment efficacy and an eventual cure of canine cancers."

After losing two of their prize Siberian Huskies to cancer, PharmaCom BioVet, Inc. founders, Gary and Sharon Berthold, were inspired to search for meaningful remedies to this dreaded killer of companion canines. In their research, they discovered two alarming facts: 1) Statistically, one in three dogs is diagnosed with cancer at some time in their life, and at least 50% of those dogs are likely to succumb. 2) Historically, there has been an alarming lack of viable treatment options and facilities for companion animals suffering from cancer. Armed with this evidence and their own personal commitment, the Bertholds founded PharmaCom BioVet, Inc. to aggressively advance the establishment of leading-edge, compassionate-care treatment centers using the latest scientific breakthroughs in cancer treatment.

Teaming up with international industry leaders such as PetScreen, LTD of Nottingham, UK and IsoTherapeutics Group, LLC of Angleton, Texas, PharmaCom BioVet, Inc. is actively engaged in supporting global research, diagnosis and novel cancer treatment methodologies. "Our ultimate goal is to eradicate cancer in companion animals. To accomplish this great task, we are collaborating with the brightest minds in cancer research and oncology treatment programs around the world," stated Berthold.

About PharmaCom BioVet, Inc.:

PharmaCom BioVet, Inc. is dedicated to advancing the veterinary care industry for companion animals by establishing state-of-the-art treatment centers for lymphoma and other forms of cancer throughout the country. The purpose of these centers is to help prolong the quality of life for companion animals with cancer and pursue the potential for complete cure. These centers will also operate under the philosophy of providing a compassionate care environment for both companion animal patients and their owners. For more information, please visit our website www.PharmaComBioVet.com.

About PetScreen, LTD:

PetScreen LTD. is headquartered and operates laboratories in Nottingham, England. Its purpose is to develop and apply new technologies directed towards improving cancer diagnosis and treatment in dogs and other companion animals. Their facilities offer services such as Canine Lymphoma Blood Tests which provide veterinarians with a simple means of screening, diagnosis and monitoring treatment of dogs with lymphoma. Their DCA program (Directed Chemotherapy Assay) helps in determining the most effective chemotherapy treatment for each individual canine cancer patient. From their UK location, they have developed a network of national and international collaborators to provide services and support to the veterinary cancer patient. For more information, please visit our website www.pet-screen.com.

About IsoTherapeutics Group, LLC:

The mission of IsoTherapeutics Group, LLC is to develop novel diagnostic and therapeutic agents for the treatment of severe diseases. ITG both develops their own technologies as well as partners with other companies to help develop pharmaceuticals. Of special interest are radiopharmaceuticals for oncology. In house expertise includes synthetic organic chemistry, chelation chemistry, radiochemistry, diagnostic and therapeutic isotopes, conjugation chemistry, pharmacokinetics, and small animal research models. For more information, please visit our website www.isotherapeutics.com.

DISCLOSURE:

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that are subject to risk and uncertainties, including, but not limited to, the impact of competitive products, product demand, market acceptance risks, fluctuations in operating results, political risk and other risks detailed from time to time in PharmaCom BioVet, Inc.'s filings with the Securities and Exchange Commission. These risks could cause PharmaCom BioVet, Inc.'s actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, PharmaCom BioVet, Inc.

Contact: Market Ideas, Inc. 877-295-3981 ext. 2 info@marketideasinc.com